These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2926418)

  • 21. Utilization and safety of fluspirilene in nonpsychotic outpatients.
    Schmidt LG
    Pharmacopsychiatry; 1989 Sep; 22(5):188-91. PubMed ID: 2813507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vision in depressive disorder.
    Bubl E; Tebartz Van Elst L; Gondan M; Ebert D; Greenlee MW
    World J Biol Psychiatry; 2009; 10(4 Pt 2):377-84. PubMed ID: 17853291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluspirilene, a long-acting injectable neuroleptic.
    Ciccarelli G; Nosé F; Zuanazzi GF
    Acta Psychiatr Belg; 1972 Nov; 72(6):736-47. PubMed ID: 4679675
    [No Abstract]   [Full Text] [Related]  

  • 24. Flupenthixol versus haloperidol in acute psychosis.
    Parent M; Toussaint C
    Pharmatherapeutica; 1983; 3(5):354-64. PubMed ID: 6844372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The frequency-contrast sensitivity of visual stimulus perception in patients with schizophrenia with the therapy of atypical and typical antipsychotic drugs].
    Shoshina II; Shelepin IuE; Semenova NB
    Fiziol Cheloveka; 2014; 40(1):43-8. PubMed ID: 25272767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluspirilene in the treatment of non-hospitalized schizophrenic patients.
    Soni SD
    Curr Med Res Opin; 1977; 4(9):645-9. PubMed ID: 590024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tilt aftereffect reveals early visual processing deficits in Parkinson's disease and in chronic schizophrenic patients on depot neuroleptic.
    Calvert JE; Harris JP; Phillipson OT
    Psychopathology; 1991; 24(6):375-80. PubMed ID: 1685795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fluspirilene in schizophrenia maintenance therapy and its interaction with dexetimide].
    Skopová J; Faltus F; Filip V; Jirák R; Karen P; Posmurová M; Dobiásová A
    Cesk Psychiatr; 1985 Dec; 81(6):414-9. PubMed ID: 3912068
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of stimulus orientation on contrast sensitivity in Parkinson's disease.
    Bulens C; Meerwaldt JD; Van der Wildt GJ
    Neurology; 1988 Jan; 38(1):76-81. PubMed ID: 3336467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selegiline for neuroleptic-induced parkinsonism.
    Gewirtz GR; Sharif Z; Cadet JL; Sarti P; Gorman JM
    Pharmacopsychiatry; 1993 Jul; 26(4):128-9. PubMed ID: 7901857
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pimozide: 16 months of follow-up].
    Bobon DP; Devroye A; Goffioul L; Pinchard A
    Acta Neurol Psychiatr Belg; 1968; 68(12):887-94. PubMed ID: 4239573
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fluspirilen and fluphenazine in schizophrenic patients. Comparative study].
    Magnus RV
    MMW Munch Med Wochenschr; 1980 Dec; 122(49):1758-60. PubMed ID: 6779147
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical efficacy of haloperidol in chronic psychotic patients.
    Lapolla A
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl l:68-77. PubMed ID: 6051725
    [No Abstract]   [Full Text] [Related]  

  • 34. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.
    Chouinard G; Annable L; Turnier L; Holobow N; Szkrumelak N
    Can J Psychiatry; 1993 Nov; 38 Suppl 4():S114-21. PubMed ID: 8306241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The visual system in Parkinson's disease.
    Bodis-Wollner I; Tagliati M
    Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159
    [No Abstract]   [Full Text] [Related]  

  • 37. [Depot neuroleptics in indications for tranquilizers: administration forms and risk in neurologic practice].
    Schmidt LG
    Verh Dtsch Ges Inn Med; 1989; 95():713-6. PubMed ID: 2603508
    [No Abstract]   [Full Text] [Related]  

  • 38. Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease.
    Haug BA; Trenkwalder C; Arden GB; Oertel WH; Paulus W
    Mov Disord; 1994 Sep; 9(5):563-70. PubMed ID: 7990852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluspirilene (Imap) in the treatment of psychosomatic complaints in hypochondriacal patients.
    Kalis D; Ten Oever GH; Erdmann JF
    Acta Psychiatr Belg; 1980; 80(3):321-8. PubMed ID: 7211423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The depot neuroleptic agent fluspirilene (author's transl)].
    Angst J; Frei M; Scharfetter Chr
    Pharmakopsychiatr Neuropsychopharmakol; 1973 Jan; 6(1):13-28. PubMed ID: 4602371
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.